Brief: Iaso Biotherapeutics And Cabaletta Bio Announce Exclusive License Agreement For Clinically Validated Cd19 Binder
11/10/2022 12:57
Oct 11 (Reuters) - Cabaletta Bio Inc CABA.O :
* IASO BIOTHERAPEUTICS AND CABALETTA BIO ANNOUNCE EXCLUSIVE
WORLDWIDE LICENSE AGREEMENT FOR CLINICALLY VALIDATED CD19 BINDER
* IASO BIOTHERAPEUTICS ENTITLED TO GET UP TO ABOUT $162
MILLION IN
PAYMENTS
* IASO BIOTHERAPEUTICS HAS RIGHT OF FIRST NEGOTIATION TO
DEVELOP &
COMMERCIALIZE CABALETTA'S PRODUCTS USING LICENSED SEQUENCE IN
GREATER CHINA REGION
Source text for Eikon: ID:nPn1BWDDqa
Further company coverage: CABA.O
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity